肝细胞生长因子及其受体与神经纤毛蛋白1在骨肉瘤中的表达及意义  

Expressions and significance of HGF,C-met and NRP1 protein in osteosarcoma

作　　者：吴同申[1] 孟彦[2] 彭圣智[3] 

机构地区：[1]济宁医学院附属医院骨科,山东济宁272029 [2]山东大学第二医院骨科,济南250033 [3]济宁医学院病理学教研室,山东济宁272067

出　　处：《重庆医学》2013年第27期3234-3235,3238,共3页Chongqing medicine

摘　　要：目的检测骨肉瘤组织中肝细胞生长因子(HGF)、肝细胞生长因子受体(C-met)和神经纤毛蛋白1(NRP1)的表达特征,探讨三者的关系及临床意义。方法选择70例骨肉瘤术后留取的蜡块及临床资料作为观察组,选择50例成熟的骨组织脱钙后的蜡块及临床资料作为对照组,应免疫组织化学技术检测2组中HGF、C-met和NRP1蛋白的表达,探讨HGF、C-met和NRP1在肿瘤患者不同临床病理特征的表达差别及其相关性。结果观察组中HGF、C-met和NRP1蛋白表达的阳性率明显高于对照组,观察组中HGF、C-met和NRP1蛋白表达的阳性率与肿瘤的转移、脉管浸润、临床分期及Ki67的表达密切相关。观察组中HGF、C-met和NRP1之间的表达具有正相关性。结论骨肉瘤组织中HGF、C-met和NRP1高表达,三者对病变的进展具有重要作用,术后联合检测HGF、C-met和NRP1的表达可能对判断预后有一定价值。Objective Todetect the expressions of HGF ,C-met and NRP1 protein in osteosarcoma and to investigate their corre-lation and the clinical significance .Methods The postoperative preserved paraffin block and the clinical data in 70 cases of osteosar-coma were taken as the observation group and 50 cases of the parraffin block of mature bone tissue after decalcification and the clin-ical data were taken as the control group .The expressions of HGF ,C-met and NRP1 protein were detected by the immunohisto-chemistry（IHC） method for investigating their expressions in the tumor patients with different clinicopathological characteristics and analyzing their relationship .Results The positive rates of HGF ,C-met and NRP1 expressions in the observation group were higher than those in the control group .The positive rates of HGF ,C-met and NRP1 expressions in the observation group were cor-related with metastasis ,vascular invasion ,clinical stage and Ki67 expression .The positive relationship was found between the ex-pressions of HGF and C-met with NRP1 of neoplasm .Conclusion The high expressions of HGF ,C-met and NRP1 in osteosarcoma play the important role in the progress of tumor lesion .The postoperative combined detection of HGF ,C-met and NRP1 protein could have certain value to predict the prognosis .

关 键 词：骨肉瘤 肝细胞生长因子 原癌基因蛋白质c—met 神经纤毛蛋白质1 

分 类 号：R738.1[医药卫生—肿瘤]